BoomRay and Novartis sign $900m deal for radioligand therapy
BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical RLT asset in a deal worth up to $900m.
Read the full article on the original site.
Read Full Article